Much of the criticism was leveled not only by academics and representatives of research organizations, but by current and former elected officials from the local level.
And, four scientists and representatives of research institutions said they had participated in planning for what is being called the Brain Activity Map project.
In a statement issued last month, Teagasc (the Irish agricultural development agency) announced it is seeking a licence to carry out field trials of GM potatoes as part of the AMIGA consortium – a group including representatives of research bodies from 15 EU countries.
The major stakeholders of EU TPs include representatives of research organizations and universities, industry, government bodies, financial institutions (banks and investment funds), venture funds, and civil society representatives.
The discourse between representatives of research and representatives of practice can succeed only if both sides recognise and accept the differences described in brief above.
The workshop proper was then attended by a combination of seven representatives of research institutions and seven WREMO practitioners, all of whom were selected and invited by ICoE CR coordinators.
The goal of this study was to evaluate the computational and economic characteristics of cloud computing in performing a large-scale data integration and analysis representative of research problems in genomic medicine.
In order to reduce this gap in LAMICs, WHO launched a program called Research for Change, which is supported by stakeholders that include policy advisers and program planners from LAMICs, representatives of national research institutes and research councils, international research organizations, editors of scientific journals, and funding agencies and donors.
The federal ministry for research, representatives of the research organizations, and law experts have also developed recommendations in order to clarify the scope of action required by university administrations.
The purposive sample [ 12] included representatives of basic research, clinical research, health economics (including statisticians), regulatory authorities, reimbursement institutions, pharmaceutical industry, patient organizations, as well as clinicians and legal experts involved in PM developments or policy making.
Our purposive sample included 17 representatives of basic research, clinical research, health economics, regulatory authorities, reimbursement institutions, pharmaceutical industry, patient organizations, as well as clinicians and legal experts involved in PM developments or policy making.
